(Adds offer details, background)
Dec 19 (Reuters) - Bristol-Myers Squibb Co BMY.N received
an offer from Japanese healthcare firm Taisho Pharmaceutical
Holdings Co Ltd 4581.T to buy the company's French
over-the-counter drugs business UPSA for $1.6 billion, the
companies said on Wednesday.
Bristol-Myers said it estimates the potential deal would be
approximately $0.04 dilutive to 2019 earnings.
The offer by Taisho, which has its presence in
anti-inflammatory analgesic, cold and flu and hair growth
segments in Japan and Southeast Asia, is structured in the form
of a "put option" agreement, the companies said. urn:newsml:reuters.com:*:nBw4XRLDha
Upon exercise of the put option, Taisho would acquire UPSA
as well as Bristol-Myers Squibb's assets and liabilities
relating to the UPSA product portfolio, the companies said.
UPSA's portfolio covers a wide range of therapeutic areas
such as pain, cough and cold, vitamins and supplements,
gastrointestinal and sleep.
The offer comes at a time when drugmakers are trying to
survive a contraction in the Japanese drug market due to
government-led price cuts and promotion of generic drugs.
Sales of the Japanese drugmaker's over-the-counter drugs in
foreign markets was worth 8.8 billion yen in April-September,
down 7.9 percent on year, according to its results.
(Reporting by Rama Venkat in Bengaluru; Editing by Sunil Nair)
((ramavenkat.raman@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 7151; Reuters Messaging:
ramavenkat.raman.thomsonreuters.com@reuters.net))